BRAF and melanoma: Activating mutations in BRAF (mainly V600E/K) have been identified in half of all melanoma cases [4], and the development of novel compounds targeting mutated BRAF[6], [19], or compounds boosting the immunological responses directed towards cancer cells [20], has given new hope to this group of patients.